We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Simvastatin for Treating Erectile Dysfunction (STED)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00947323
First Posted: July 28, 2009
Last Update Posted: September 27, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Santa Casa de Porto Alegre
  Purpose
This is a randomized clinical trial, double-blind, placebo controlled, to verify if simvastatin can improve erectile dysfunction in men with endothelial dysfunction, without any cardiac disease.It is hypothesized that the simvastatin can improve the endothelial function, improving the nitric oxide liberation in corpora cavernosa of the penis, resulting in improvement of erection.

Condition Intervention Phase
Erectile Dysfunction Vascular Disease Detected C Reactive Protein Drug: Simvastatin Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of Simvastatin in the Penile Erection: a Randomized, Double-blind Clinical Trial

Resource links provided by NLM:


Further study details as provided by Santa Casa de Porto Alegre:

Primary Outcome Measures:
  • Penile erection

Enrollment: 41
Study Start Date: January 2006
Study Completion Date: December 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: Placebo
Experimental: Simvastatin
Treatment arm.
Drug: Simvastatin
simvastatin 20 daily for six months.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Erectile dysfunction
  • Elevated C reactive protein
  • Able to adhere the protocol

Exclusion Criteria:

  • Diabetes mellitus
  • Cardiac disease
  • Cerebral vascular disease
  • Hypogonadism
  • Any contraindication to simvastatin
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Eduardo Touguinha Mastalir, Santa Casa de Porto Alegre
ClinicalTrials.gov Identifier: NCT00947323     History of Changes
Other Study ID Numbers: STED
First Submitted: July 27, 2009
First Posted: July 28, 2009
Last Update Posted: September 27, 2010
Last Verified: September 2010

Keywords provided by Santa Casa de Porto Alegre:
simvastatin
endothelial dysfunction
erectile dysfunction

Additional relevant MeSH terms:
Erectile Dysfunction
Vascular Diseases
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Cardiovascular Diseases
Simvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors